Original Articles
Vol. 18 (2023)

INTENSITY MODULATED RADIATION THERAPY IN THE ADJUVANT TREATMENT OF RESECTED GASTRIC CANCER: A RETROSPECTIVE DOSIMETRIC AND CLINICAL ANALYSIS

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: September 3 2025
3
Views
1
Downloads

Authors

The European Society for Medical Oncology guidelines recommend adjuvant chemoradiation for patients with resected gastric cancer who have not undergone an appropriate D2 lymphadenectomy or have involved margins. In this setting, due to the requirement to cover large irradiation volumes and to deliver concomitant systemic therapy, treatment-related toxicities remain a concern. With the goal of assessing safety and feasibility of adjuvant radiotherapy, we collected data of patients with resected gastric cancer, who underwent Intensity Modulated Radiation Therapy to 50.4 Gy, concurrent with fluoropyrimidine based chemotherapy at our institution, between January 2016 and January 2022. In this study, we examined dose distribution to PTV and organs at risk, demonstrating safety and feasibility of this treatment without significant acute or late toxicities.

Downloads

Download data is not yet available.

Citations

How to Cite



INTENSITY MODULATED RADIATION THERAPY IN THE ADJUVANT TREATMENT OF RESECTED GASTRIC CANCER: A RETROSPECTIVE DOSIMETRIC AND CLINICAL ANALYSIS. (2025). EuroMediterranean Biomedical Journal, 18, 125-130. https://doi.org/10.3269/ebmj.2023.48

Most read articles by the same author(s)